Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 545Squamous Cell Carcinoma of Head and Neck 281Head and Neck Neoplasms 258Lung Neoplasms 240Uterine Cervical Neoplasms 182Stomach Neoplasms 172Esophageal Neoplasms 161Nasopharyngeal Carcinoma 127Urinary Bladder Neoplasms 117Esophageal Squamous Cell Carcinoma 116Neoplasms 115Small Cell Lung Carcinoma 106Ovarian Neoplasms 92Breast Neoplasms 92Neoplasm Metastasis 90Cholangiocarcinoma 77Carcinoma, Squamous Cell 76Pancreatic Neoplasms 73Biliary Tract Neoplasms 72Oropharyngeal Neoplasms 57Mesothelioma, Malignant 57Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 46Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Triple Negative Breast Neoplasms 39

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × Cisplatin × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡